Plain-English translation of NCT05971108 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new blood test called Elecsys GAAD to see if it can detect liver cancer earlier in people with liver cirrhosis. Right now, doctors use standard tests to screen for liver cancer, but these often find it too late when treatment options are limited. Researchers want to know if this new blood test, used alongside standard care, can catch cancer at an earlier, more treatable stage.
People with cirrhosis are at high risk of developing liver cancer, which is often found too late for effective treatment. This medication aims to improve early detection by providing doctors with another tool to catch cancer sooner, when patients have more treatment options and better chances of survival.
You will continue your regular liver cancer screening appointments, but will also have blood samples taken as part of this study. The new blood test will be done alongside your standard screening tests so doctors can compare how well the new test works. Your participation involves regular clinic visits where blood will be drawn — the study will track you over time to see if the new test catches cancers earlier than usual screening methods.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United Kingdom
Sponsor
Manchester University NHS Foundation Trust
Collaborators
University of Manchester, Unity Insights
Enrollment target
~657 participants
Started
January 2024
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.